INTRODUCTION {#s1}
============

Gastric cancer (GC), or stomach cancer, is a type of cancer that derives from the mucus-producing cells on the inside lining of the stomach and among them the most common GC is adenocarcinoma. GC is the fifth most common cancer globally and the third most common cause of mortality associated with cancers ([@BIO041343C19]). Additionally, Wang and his colleagues have reported that in China it ranks second among cancer mortality and its incidence still keeps rising ([@BIO041343C30]). In spite of substantial improvements in surgical and chemotherapy treatments, the 5-year overall survival rate remains unsatisfactory by reason of diagnosis of the majority of patients with advanced GC accompanied by the relapse or metastasis ([@BIO041343C15]). Furthermore, the pathogenesis of GC is intricate and GC, the molecular mechanisms of GC tumorigenesis and progression remain poorly understood. In recent years, research has reported that GC develops through the accumulation of genetic and epigenetic alterations ([@BIO041343C16]). Therefore, it is important to discover the underlying molecular mechanism of tumorigenesis in order to promote the development of new and promising therapies for GC patients.

Recently, increasing studies have showed that long noncoding RNAs (lncRNA) with limited or no protein-coding capacity are dysregulated in cancer progression ([@BIO041343C4]; [@BIO041343C29]). To date, many lncRNA expression alterations of tumor-related genes have been reported to be associated with GC development. LncRNA maternally expressed gene 3 (MEG3) is associated with metastatic GC, and its overexpression can constrain cell proliferation, migration, invasion and enhance cell apoptosis via sequestering oncogenic miR-181 in GC cells ([@BIO041343C20]). Gastric adenocarcinoma predictive long intergenic noncoding RNA, which is termed GAPLINC, has been shown to contribute to the malignant phenotype, including the increased proliferation and invasiveness of GC cells, by activating CD44 expression, and inhibition of GAPLINC produces a significant reduction in tumor growth *in vivo* ([@BIO041343C20]).

Growth arrest-specific transcript 5 (GAS5) was first confirmed in mouse NIH 3T3 cells and identified as a possible tumor suppressor genes in many cancers ([@BIO041343C5]). GAS5 has been reported to be aberrantly expressed in some cancers, including lung cancer ([@BIO041343C31]), cervical cancer ([@BIO041343C1]), breast cancer ([@BIO041343C21]) and gastric cancer, and plays important roles in cell processes such as proliferation, invasion, migration and apoptosis. Growing studies have disclosed the functional mechanism of lncRNAs in tumorigenesis by sponging specific microRNAs (miRNAs) and their direct interaction are attracting multi-field researchers\' attention ([@BIO041343C6]; [@BIO041343C28]). However, the roles and potential mechanisms of GAS5 in GC are still not well clarified yet.

Here, bio-informatics analyses revealed a potential interaction between GAS5 and miRNA-106a-5p. Further, we explored the expression profiles of GAS5 and miRNA-106a-5p in GC tissues and cell lines and analyzed their relationship. Moreover, functional and mechanism experiments were conducted *in vitro* and *in vivo*. Our findings provided a novel insight for the roles of GAS5 and miRNA-106a-5p in the development of GC and the regulatory mechanism involved.

RESULTS {#s2}
=======

Decreased expression of GAS5 accompanied with increased miR-106a-5p in GC tissues and cells {#s2a}
-------------------------------------------------------------------------------------------

Firstly, the expression levels of GAS5 and miRNA-106a-5p in patients with GC were determined by qRT-PCR. As shown in [Fig. 1](#BIO041343F1){ref-type="fig"}A and B, GAS5 levels were significantly reduced in GC tissues, while the levels of miRNA-106a-5p were obviously higher than the adjacent normal tissues. And the analyses of GAS5 expression in different TNM stages showed that a significant reduction of GAS5 levels in GC tissues at stage 3/4 was observed compared with stage 1/2 ([Fig. 1](#BIO041343F1){ref-type="fig"}C). Then, the expression patterns of GAS5 and miRNA-106a-5p were compared by Pearson\'s correlation coefficient and the presented results showed that the expression of GAS5 was negatively correlated with miRNA-106a-5p expression ([Fig. 1](#BIO041343F1){ref-type="fig"}D). In addition, the reduction of GAS5 levels ([Fig. 1](#BIO041343F1){ref-type="fig"}E) and the increase of miRNA-106a-5p levels ([Fig. 1](#BIO041343F1){ref-type="fig"}F) were also presented in GC cell lines (HCG-27 and SGC-7901) compared with human gastric epithelial cell line RGM-1. These results suggested that the aberrant expression of GAS5 and miRNA-106a-5p had a close relationship with GC development. Fig. 1.**Decreased expression of GAS5 accompanied with increased miR-106a-5p in GC tissues and cells.** Expression levels of GAS5 and miR-106a-5p were determined by qRT-PCR. The expression analyses of GAS5 (A) and miR-106a-5p (B) in GC and paired adjacent normal tissues from 21 GC patients. (C) The expression analyses of GAS5 in GC tissues at stages 1/2 and 3/4. (D) Pearson\'s correlation between GAS5 and miR-106a-5p levels. The expression analyses of GAS5 (E) and miR-106a-5p (F) in human gastric epithelial cell line RGM-1, GC cell lines (HCG-27 and SGC-7901). \**P*\<0.05.

GAS5 interacted with miR-106a-5p and negatively regulated its expression in GC cells {#s2b}
------------------------------------------------------------------------------------

Given the above results, we speculated the GAS5 could sponge to miRNA-106a-5p. Therefore, bioinformatics analyses were performed by the software MegAlign. As presented in [Fig. 2](#BIO041343F2){ref-type="fig"}A, miRNA-106a-5p might be a candidate binding miRNA of GAS5. Further, the results from dual-luciferase reporter assay showed that the luciferase activity from GAS5-WT was significantly decreased in miRNA-106a-5p transfected group. However, miRNA-106a-5p transfection had no significant effects on the luciferase activities of GAS5-MUT in 293T cells ([Fig. 2](#BIO041343F2){ref-type="fig"}B). Moreover, qRT-PCR analyses showed that GAS5 overexpression significantly repressed the expression of miRNA-106a-5p in HCG-27 ([Fig. 2](#BIO041343F2){ref-type="fig"}C) and SGC-7901 ([Fig. 2](#BIO041343F2){ref-type="fig"}D) cells. Taken together, these data suggested that GAS5 directly targeted miR-106a-5p and negatively regulated its expression in GC cells. Fig. 2.**GAS5 interacted with miR-106a-5p and negatively regulated its expression in GC cells.** (A) Bioinformatics analyses were conducted to predict the possible binding site of miR-106a-5p in GAS5. (B) Dual-luciferase reporter assay was performed to determine the interaction of GAS5 and miR-106a-5p in 293T cells at 48 h. qRT-PCR analyses of miR-106a-5p in the HCG-27 (C) and SGC-7901 (D) cells transfected with GAS5, GAS5+miR-106a-5p, or vector. \**P*\<0.05.

GAS5 overexpression inhibited proliferation and induced apoptosis via regulating miR-106a-5p in GC cells {#s2c}
--------------------------------------------------------------------------------------------------------

To further explore the biological roles of GAS5 and miRNA-106a-5p, a series of functional experiments were carried out. As exhibited in [Fig. 3](#BIO041343F3){ref-type="fig"}A and B, overexpression of GAS5 significantly constrained the proliferation of HCG-27 and SGC-7901 cells and miRNA-106a-5p upregulation significantly weakened the inhibitory induced by GAS5 overexpression. Furthermore, the capacity of colony formation in HCG-27 ([Fig. 3](#BIO041343F3){ref-type="fig"}C) and SGC-7901 ([Fig. 3](#BIO041343F3){ref-type="fig"}D) was also significantly inhibited by GAS5 upregulation, while miRNA-106a-5p overexpression eased the effects. In addition, GAS5 upregulation obviously promoted apoptosis in HCG-27 ([Fig. 4](#BIO041343F4){ref-type="fig"}A) and SGC-7901 ([Fig. 4](#BIO041343F4){ref-type="fig"}B) cells, whereas miRNA-106a-5p overexpression evidently inverted the effect of GAS5 upregulation. As shown in [Fig. 4](#BIO041343F4){ref-type="fig"}C and D, GAS5 upregulation also significantly enhanced the expression of cleaved caspase-3 in HCG-27 and SGC-7901 cells and miRNA-106a-5p overexpression weakened the positive effects. These data implied that GAS5 overexpression suppressed proliferation and induced apoptosis via regulating miR-106a-5p in GC cells. Fig. 3.**GAS5 overexpression inhibited proliferation and colony formation via regulating miR-106a-5p in GC cells.** CCK-8 assays were used to detect proliferation of HCG-27 (A) and SGC-7901 (B) cells transfected with GAS5, GAS5+miR-106a-5p, or vector at indicated times (0, 1, 2, 3, and 4 days). Colony formation assays were conducted to measure the ability of cell survival in the transfected HCG-27 (C) and SGC-7901 (D) cells. \**P*\<0.05.Fig. 4.**GAS5 overexpression induced apoptosis via regulating miR-106a-5p in GC cells.** Flow cytometry analyses of apoptosis rates of the transfected HCG-27 (A) and SGC-7901 (B) cells at 24 h. Western blot assays were carried out to determine expression of cleaved caspase-3 in the transfected HCG-27 (C) and SGC-7901 (D) cells at 48 h. \**P*\<0.05.

GAS5 overexpression repressed invasion and migration via regulating miR-106a-5p in GC cells {#s2d}
-------------------------------------------------------------------------------------------

As shown in [Fig. 5](#BIO041343F5){ref-type="fig"}A and B, transwell assays showed that upregulation of GAS5 significantly reduced the capability of GC cell invasion compared with control group, while the introduction of miRNA-106a-5p obviously weakened the repressive effects. Moreover, wound healing assays revealed that overexpression of GAS5 markedly constrained the migration of HCG-27 ([Fig. 5](#BIO041343F5){ref-type="fig"}C) and SGC-7901 ([Fig. 5](#BIO041343F5){ref-type="fig"}D) cells, and miRNA-106a-5p significantly inverted the suppressive effects of overexpression of GAS5. In addition, expression of MMP-2 and MMP-9 was significantly repressed in GAS5 overexpressing HCG-27 ([Fig. 5](#BIO041343F5){ref-type="fig"}E) and SGC-7901 ([Fig. 5](#BIO041343F5){ref-type="fig"}F) cells, while miRNA-106a-5p upregulation obviously weakened the repressive effects. These results suggested that GAS5 overexpression repressed invasion and migration via regulating miR-106a-5p in GC cells. Fig. 5.**GAS5 overexpression repressed invasion and migration via regulating miR-106a-5p in GC cells.** Transwell assays were carried out to assess the invasion capability of HCG-27 (A) and SGC-7901 (B) cells transfected with GAS5, GAS5+miR-106a-5p, or vector at 0 and 24 h. And wound healing assays were used to determine the migration capability of the transfected HCG-27 (C) and SGC-7901 (D) cells. Western blot assays were carried out to determine expression of MMP-2 and MMP-9 in the transfected HCG-27 (E) and SGC-7901 (F) cells at 48 h.

GAS5 overexpression inhibited GC growth via regulating miR-106a-5p *in vivo* {#s2e}
----------------------------------------------------------------------------

To determine the function of GAS5 in tumor growth *in vivo*, the SGC-7901 cells transfected with GAS5, GAS5+miRNA-106a-5p or vector were injected subcutaneously into nude mice. The detection of tumor size and weight showed that the volume of xenograft tumors with SGC-7901 cells expressing GAS5 was smaller than that of the control group, and miRNA-106a-5p overexpression partially inversed the roles of GAS5 overexpression in GC tumor formation ([Fig. 6](#BIO041343F6){ref-type="fig"}A,B). These results suggested that GAS5 overexpression inhibited growth of GC xenograft tumor via regulating miR-106a-5p. Fig. 6.**GAS5 overexpression inhibited GC growth via regulating miR-106a-5p *in vivo*.** SGC-7901 cells transfected with GAS5, GAS5+miR-106a-5p, or vector were subcutaneously injected into the right side of the posterior flank of mouse. Xenograft tumor growth curves (A) and tumor weights (B) for nude mice were detected. *N*=7. \**P*\<0.05.

GAS5/miR-106a-5p axis negatively regulated the activation of the Akt/mTOR pathway {#s2f}
---------------------------------------------------------------------------------

The Akt/mTOR pathway is an intricate intracellular pathway and its alterations are crucial in tumorigenesis ([@BIO041343C3]). To further explore the mechanism by which GAS5 and miRNA-106a-5p affected the GC progression, a western blot assay was conducted to detect the effect of GAS5 and miRNA-106a-5p on activity of the Akt/mTOR pathway *in vitro* and *in vivo*. The results from the western blot demonstrated that GAS5 upregulation significantly diminished the expression levels of p-Akt and p-mTOR, while the introduction of miRNA-106a-5p partially inverted the repressive roles of GAS5 upregulation *in vitro* and *in vivo* ([Fig. 7](#BIO041343F7){ref-type="fig"}A,B). These data showed roles of GAS5/miR-106a-5p axis in reducing activation of the Akt/mTOR pathway in GC. Fig. 7.**GAS5/miR-106a-5p axis negatively regulated the activation of the Akt/mTOR pathway.** (A) Western blot assays were conducted to detect the expression of Akt, p-Akt, mTOR and p-mTOR in the HCG-27 and SGC-7901 cells transfected with GAS5, GAS5+miR-106a-5p, or vector. (B) Western blot analyses of Akt, p-Akt, mTOR and p-mTOR expression in xenograft tumor tissues. \**P*\<0.05: compared with vector-treated mice group, and ^\#^*P*\<0.05: compared with the values of GAS5-treated mice.

DISCUSSION {#s3}
==========

In the last decade a growing number of cancer-related lncRNAs have been discovered; they are reported to be often abnormally expressed in numerous cancer cells and lead to carcinogenesis by spatially and temporally regulating expression patterns ([@BIO041343C17]). Recently, lncRNA linc00460 has been found to accelerate cell migration and invasion through inducing epithelial-mesenchymal transition (EMT) in lung cancer cells, which contributes to tumor progression and metastasis ([@BIO041343C11],[@BIO041343C12]). Although great progress has been made in studying lncRNAs, their exact roles in GC are still not completely clear. GAS5, a lncRNA, is originally identified in growth-arrested mouse NIH 3T3 fibroblasts ([@BIO041343C24]). Afterwards, GAS5 has been found to be aberrantly expressed in many cancers and other diseases and plays crucial roles in pathological processes, such as cell proliferation, apoptosis, tumor growth and metastasis ([@BIO041343C26]). Pickard and his colleagues have presented abnormally low levels of GAS5 expression in prostate cancer cells and GAS5 upregulation boosts apoptosis and reduces 22Rv1 cell survival ([@BIO041343C22]). In pancreatic cancer the expression level of GAS5 has been verified to be obviously reduced in pancreatic cancer tissues, and GAS5 upregulation represses cell proliferation by suppressing expression of cyclin-dependent kinase 6 (CDK6) *in vitro* and *in vivo* ([@BIO041343C14]). In GC cells, GAS5 has been found to be downregulated and constrains proliferation through the PTEN/Akt/mTOR pathway by sponging miR-222 ([@BIO041343C10]). In our study, we found that GAS5 expression was decreased in GC tissues and cells, and there was a significant reduction of GAS5 levels in GC tissues at stage 3/4. Moreover, overexpression of GAS5 could restrain proliferation, invasion and migration as well as promote apoptosis in GC cells. These data revealed a crucial function of GAS5 in GC development.

miRNAs function in vital regulatory roles in post-transcriptional expression of target genes and their aberrant expression is involved in many human diseases, including cancers ([@BIO041343C11],[@BIO041343C18]). Currently, some miRNAs have been reported to be related to GC. miR-25 has been reported to be upregulated in plasma and primary tumor tissues of GC patients and enhances GC progression by directly targeting TOB1 ([@BIO041343C7],[@BIO041343C8]). Increased miR-34a could boost the sensitivity to DDP of SGC7901/DDP cells by suppressing cell proliferation and promoting cell apoptosis via targeting MET ([@BIO041343C35]). miRNA-106a, functioning as a cancer-promoting gene, has been shown to be correlated with carcinogenesis in many cancers, including GC ([@BIO041343C34]; [@BIO041343C27]). In our study, our results showed that miRNA-106a-5p was significantly upregulated in GC tissues and cells. In recent years a growing number of reports have shown that the disorders of competitive endogenous RNA (ceRNA) networks tend to result in carcinogenesis via tumor suppressors and oncogenes through their ceRNA function ([@BIO041343C2]; [@BIO041343C13]; [@BIO041343C36]). Nonetheless, the ceRNA hypothesis has provided a novel viewpoint to explore disease processes by regulating ceRNA networks through miRNA competition or sponge for cancer therapy. In our results what was interesting was that the expression of GAS5 was negatively correlated with miRNA-106a-5p expression. We speculated that GAS5 played important roles in GC progression by interacting with miRNA-106a-5p. As we had hypothesized, GAS5 directly targeted miR-106a-5p and negatively regulated its expression in GC cells. Furthermore, overexpression of miR-106a-5p could partially invert the effects of GC overexpression on cell proliferation, apoptosis, invasion, migration and xenograft tumor growth. All these results suggested that GAS5 could constrain GC progression.

miRNAs play vital roles in regulation of cell signaling and homeostasis. Plenty of studies have shown that aberrations in various cellular signaling pathways are involved in regulating tumor development and progression ([@BIO041343C23]). Mourtada et al. have found that GAS5 upregulation can not result in growth arrest by itself, but it enhances sensitivity to treatments that induce apoptosis through affecting diversified pathways ([@BIO041343C18]). Many reports have revealed that PI3K/Akt/mTOR, a main intracellular signaling pathway, has participated in cancer processes such as cellular survival, proliferation, growth, invasiveness and other functions of co-carcinogenic factor ([@BIO041343C3]; [@BIO041343C7],[@BIO041343C8]). As presented in our results, western blot analyses showed that with the treatment of GAS5 transfection the reducing phosphorylation of Akt and mTOR was determined, which was consistent with previous studies ([@BIO041343C33]; [@BIO041343C9]). And miR-106a-5p overexpression could partially invert the repressive effects of GAS5 overexpression on activation of the Akt/mTOR pathway. A previous study has reported that miRNA-106a-5p can target PTEN mRNA and reduce its expression in GC cells, which resulted in promoting G0/G1 to S phase transition and proliferation in cells ([@BIO041343C32]). In addition, PTEN, a negative regulator of the cell cycle, has been confirmed to repress the PI3K-AKT-mTOR pathway via its lipid phosphatase activity and then govern survival, proliferation, energy metabolism and cellular architecture ([@BIO041343C25]). Based on these results, we suggested that GAS5 inhibited tumorigenesis and development of GC by targeting miRNA-106a-5p through reducing the activation of the Akt/mTOR pathway.

Conclusion {#s4}
==========

In conclusion, our present study revealed the decreased GAS5 and increased miR-106a-5p in GC tissues and cell lines. In addition, GAS5 competitively binds to miRNA-106a-5p and inhibits its expression in GC cells. Further, our results showed that GAS5 overexpression constrained cell proliferation, invasion, migration and tumor growth, and also induced apoptosis by regulating miR-106a-5p through the Akt/mTOR pathway. Our findings provide a novel regulatory axis of GC progression, which may boost further exploration of functional lncRNA-directed diagnostic and therapeutic agents in gastric cancer.

MATERIALS AND METHODS {#s5}
=====================

Patients and tissue samples {#s5a}
---------------------------

The fresh-frozen GC and paired adjacent normal tissue samples were obtained between from January 2017 to May 2018 from 21 GC patients who underwent surgery and did not receive any therapy in prior to the operation at the First Affiliated Hospital of Zhengzhou University. Written informed consent was obtained from all patients. The use of samples for the study was approved by the Research Ethics Committee of the First Affiliated Hospital of Zhengzhou University. All tissues were frozen in liquid nitrogen and then stored at −80°C for further qRT-PCR analyses.

Cell culture {#s5b}
------------

Human gastric epithelial cell line RGM-1 cell and gastric cancer cell lines (HCG-27 and SGC-7901) were used in this study and all cell lines were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). All cell lines were routinely grown at 37°C in an atmosphere of 5% CO~2~ in RPMI 1640 medium (Corning, VA, USA) supplemented with 10% inactivated fetal bovine serum (FBS, Corning, VA, USA).

HEK293T cells were obtained from American Type Culture Collection (ATCC; Shanghai, China) and propagated in Dulbecco\'s Modified Eagle\'s Medium (Gibco; Invitrogen; Life Technologies, Germany) containing with 10% FBS under the above conditions.

Gene overexpression {#s5c}
-------------------

The complementary DNA (cDNA) encoding GAS5 or miRNA-106a-5p was PCR-amplified and subcloned into pCDH-CMV-MCS-EF1-copGFP-T2A-Puro vector (GenePharma, Shanghai, China). The recombinant vectors containing GAS5 or miRNA-106a-5p genes were co-transfected with pCMV-Δ8.2 and pCMV-VSV-G into HEK293T cells to generate retroviral particles overexpressing GAS5 or miRNA-106a-5p, which were named as LV-GAS5 and LV-miR-106a-5p, respectively.

HCG-27 and SGC-7901 cells were transduced with GAS5 overexpressing lentivirus-containing media and screened with puromycin (2 μg/ml) to harvest the stable cells. After 1 week cell pools were obtained and expanded. miRNA-106a-5p overexpressing lentivirus was used to infect the GAS5 overexpressing HCG-27 and SGC-7901 cells to gain cells with stable co-expression of GAS5 and miRNA-106a-5p.

Luciferase reporter assay {#s5d}
-------------------------

The GAS5 fragment sequences holding the binding sites of miRNA-106a-5p were synthesized and then inserted into the pGL3 luciferase reporter vector (Promega, WI, USA). HEK293T cells were co-transfected with the constructs encompassing the wild-type GAS5 (GAS5-WT) or mutant GAS5 (GAS5-MUT), along with the pRL-TK control vector and miRNA-106a-5p mimics (miRNA-106a-5p) or mimic control (miR-control). After 48 h of transfection, the cells were collected and detected with Dual Luciferase Assay kit (Promega) in line with the manufacturer\'s instructions.

RNA extraction and quantitative real time PCR {#s5e}
---------------------------------------------

Total RNA containing small RNA was prepared from either gastric cancer tissues or cells by TRIzol Reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in accordance with the manufacturer\'s instructions. Concentration and quality of RNA were measured using the NanoDrop ND-1000 spectrophotometer (NanoDrop Tech., Inc. Wilmington, DE, USA). Afterwards, 1 μg of RNA for GAS5 was used to synthesize cDNA using high Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) in a T-Professional Basic, Biometra PCR System (Applied Biosystems). Reverse transcription of miRNA-106a-5p was performed to synthesize cDNA using TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems). GAPDH and U6 as the endogenous controls were chosen to normalize the data of GAS5 and miRNA-106a-5p expression, respectively. All primers used in this study are shown in [Table 1](#BIO041343TB1){ref-type="table"}.Table 1.**Primers used for quantitative real time PCR**

CCK-8 assay {#s5f}
-----------

CCK-8 assays were used to assess the proliferation of cells. Briefly, the transfected cells at a density of 2×10^3^ cells/well were plated in 96-well plate. After incubation for the indicated times (0, 1, 2, 3 and 4 days), the CCK-8 solution (DOJINDO, Japan) was added into each well according the manufacturer's instructions. The optical density at 450 nm was determined by a microplate reader (Synergy4; BioTek Instruments, Inc., Winooski, VT, USA).

Colony formation assay {#s5g}
----------------------

The transfected cells (600 cells/well) were plated into six-well plates and cultured at 37°C in an atmosphere of 5% CO~2~ in RPMI 1640 medium. 2 weeks later the cells were fixed and stained with 0.1% Crystal Violet. The number of colonies, which were confirmed as \>50 cells/colony, was counted.

Apoptosis analyses {#s5h}
------------------

Apoptosis rates of the transfected cells were detected by flow cytometric analyses. To measure the apoptosis rates in the transfected cells, the cells were grown for 24 h and then gathered with trypsin. Apoptosis analysis was performed by a double staining Annexin V and 7-AAD Apoptosis Detection Kit (BD Pharmingen, San Jose, CA, USA) following the manufacturer's instructions. Apoptosis analyses were analyzed with a flow cytometer (FACScan; BD Biosciences).

Wound healing assay {#s5i}
-------------------

Cell migration capability was determined by wound healing assay. The transfected cells were plated in a 24-well plate with complete RPMI 1640 medium. A 10-μl sterile pipette tip was used to make a vertical wound until cell confluence rate was about approximately 100%. The cells were washed with PBS to discard the detached cells and continuously cultured in FBS-free RPMI-1640 with for 24 h. Images were photographed at 0 and 24 h under an optical microscope (Olympus, Tokyo, Japan).

Matrigel invasion assay {#s5j}
-----------------------

Cell invasion ability was assessed by matrigel invasion assay. The transfected cells were plated on the upper migration chambers (8-μm pore size; Millipore, Switzerland) coated with Matrigel (Sigma-Aldrich, USA) and incubated in free-FBS RPMI 1640 medium. 500 μl of RPMI 1640 medium supplemented with 20% FBS was added into the lower chamber. After incubation for 24 h, the invasive cells located on the lower surface of the chamber were stained with 0.05% Crystal Violet (Beyotime, Shanghai, China). The number of migrated cells was detected under an optical microscope (Olympus).

*In vivo* animal studies {#s5k}
------------------------

21 4-week-old female BALB/c athymic nude mice were purchased from the Experimental Animal Centre of Zhengzhou University and maintained under specific pathogen-free conditions. Animal experiments were approved by the Animal Care and Use Committee of The First Affiliated Hospital of Zhengzhou University. The SGC-7901 cells transfected with GAS5, GAS5+miRNA-106a-5p or vector were resuspended at a concentration of 5×10^7^ cells/ml. 200 μl of the suspended cells was subcutaneously injected into the right side of the posterior flank of each mouse. Tumor growth was monitored every 5 days, and tumor volumes were calculated using the equation V=π/6×D×d^2^ (where: V, volume; D, longitudinal diameter; d, latitudinal diameter). At 35 days post-injection, all mice were euthanized, and the weight of each tumor was measured. Tumor tissues were used for western blot analyses.

Western blot {#s5l}
------------

Total proteins were extracted from tissue and the transfected cells using RIPA buffer (Beyotime) encompassing protease inhibitors. The protein lysates were separated by 10% SDS and then transferred onto a polyvinylidene fluoride membrane. The proteins were blocked with 5% non-fat milk in PBST (0.2% Triton X-100 in PBS) and the membranes were incubated with primary antibodies. The antibodies used in this study were as follow: cleaved caspase-3 (ab2302; Abcam, Cambridge, UK; 1:1000), MMP-2 (ab37150; Abcam; 1:1000), MMP-9 (ab38898; Abcam; 1:2000), AKT (ab8805; Abcam; 1:1000), p-AKT (ab81283; Abcam; 1:1000), mTOR (2732; Abcam; 1:1000), p-mTOR (ab109268; Abcam; 1:1000), and β-actin (ab8226; Abcam; 1:1000). After incubation with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room temperature, the immunoreactive proteins were signaled by using enhanced chemiluminescence (CEL; Thermo Fisher Scientific). Finally, the protein expression levels were analyzed by ImageQuant software (LLC, Sunnyvale, CA, USA).

Statistical analysis {#s5m}
--------------------

The experiments were repeated at least three times. All data are shown as the mean±standard deviation (s.d.). Statistical analyses were carried out by GraphPad Prism software (GraphPad, La Jolla, CA, USA). The Student\'s *t*-test was applied for comparisons between two groups and *P*\<0.05 was considered statistically significant.
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